ADVENT
ADVENT is a medical education programme designed to advance the understanding of type 2 inflammation
Developed in collaboration with an expert steering committee of leading Australian respiratory, dermatology and immunology specialists, ADVENT disseminates the science behind type 2 inflammatory diseases such as atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) supporting patient management and care.
The ADVENT Interactive Clinical Tutorials are now in their fourth year. Access the latest from the respiratory and dermatology series here and find out more about coming events. ASPIRE, a practically focused, online Interactive Clinical Tutorial developed for respiratory nurses by respiratory nurses that aims to share best practices, gain insights and share experiences. Access the latest ASPIRE events here and find out more about coming events.
Latest information and presentations
ADVENT Respiratory
Find out more about the Australian ADVENT respiratory programme developed in collaboration with an expert steering committee
ADVENT Dermatology
Find out more about the Australian ADVENT Dermatology programme developed in colaboration with an expert steering committee
ADVENT ASPIRE
ASPIRE is a practically focused programme developed for respiratory nurses by respiratory nurses
Watch the 2020–2022 ADVENT and ASPIRE series developed and endorsed by Australian and international experts
At ADVENTprogram.com you can:
-
Access medical education resources
- Review the latest science for Type 2 inflammatory diseases
- Explore your specific interests – select materials by category or topic
Access to ADVENTprogram.com is restricted to healthcare professionals. Registration is required to view content.
Dupixent (dupilumab) PBS Information: Authority Required.
Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with: chronic severe atopic dermatitis: OR uncontrolled severe asthma. This product is not listed on the PBS for: children 6 months to 11 years of age with severe atopic dermatitis; children 6-11 years of age with moderate to severe asthma; adults with uncontrolled chronic rhinosinusitis with nasal polyps; or adults with moderate-to-severe prurigo nodularis.
Please review full product Information before prescribing Dupixent (dupilumab). Full Product Information is available from Sanofi-aventis Australia pty ltd here or by contacting 1800 818 806.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems
MAT-AU-2300898(v4.0) | OCTOBER 2023